CLINICAL_TRIALS
trial_result
· 2010-12-31
Clinical Trial Update: Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors [Phase 3]
Summary
Phase 3 trial comparing daily sunitinib versus imatinib in patients with gastrointestinal stromal tumors has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Gastrointestinal Stromal Tumor | Phase 3 | Status: TERMINATED | Results posted: 2010-12-31